TG Therapeutics raises 2026 sales forecast as BRIUMVI drives 63% revenue growth in Q1

TG Therapeutics remains a "Strong Buy" as its drug BRIUMVI shows strong market momentum with 63% year-over-year sales growth in Q1. The company raised its 2026 BRIUMVI sales guidance to $885–$900 million, supported by successful Phase 3 trial results that may expand its label and competitive position in the RMS market. TG Therapeutics also benefits from a solid cash position, $500 million in non-dilutive capital, and an expanded share repurchase program, enhancing its financial strength and flexibility.